Sai Parenterals wins ₹1,300-crore Australia OTC deal (2026)

Deal announcement and why it matters

Hyderabad-based pharmaceutical formulations company Sai Parenterals Limited said it has secured a large overseas supply arrangement through its Australia arm, marking a fresh milestone in its regulated-market push. The company’s Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has entered into a new agreement to supply OTC (over-the-counter) medicines to leading pharmacy networks in Australia. Sai Parenterals disclosed the deal value at AUD 202 million, which it said is around ₹1,300 crore. The contract is set to run for 7.5 years, giving Noumed a long visibility runway in a market where retail pharmacy chains are a key route to consumers.

The announcement also comes at a time when the company has recently moved into a larger consolidated structure after acquiring a controlling stake in Noumed. With the acquisition completed in November 2025 and consolidated from that date, Sai Parenterals’ reported numbers for FY26 include only part-year contributions from its Australian business. Against that backdrop, the long-duration OTC supply contract adds another layer of operating clarity to the company’s overseas platform.

What Noumed signed in Australia

The agreement is described as a supply deal for OTC medicines with top-tier pharmacy networks in Australia. Sai Parenterals said the contract will be implemented from July 1, 2026. The company also indicated that the deal is structured to deliver average annual business of about AUD 27 million.

Beyond the contracted revenue stream, the agreement also sets an operating target: adding 12 new products each year under the contract. That product cadence matters because OTC portfolios often depend on continuous launches and line extensions to hold shelf space in pharmacy chains. Sai Parenterals identified Anil KK from Sai Parenterals and Mark Thulborne from Noumed Pharma in connection with the deal.

Duration, extension option, and product additions

Sai Parenterals said the initial term is 7.5 years. The agreement also includes an option to extend the contract by another three years, subject to mutual consent from both parties. That extension clause gives the arrangement a potential life of 10.5 years, depending on performance and partner alignment.

The company has not disclosed product-level pricing or margin terms in the provided information. But it did specify the annual business expectation and the annual new-product plan, which together frame the operating scale the company is preparing for. The start date of July 1, 2026 sets a clear timeline for ramp-up planning in procurement, regulatory readiness, packaging, and supply chain execution.

Noumed acquisition and consolidation context

Sai Parenterals ended FY26 as a newly listed company, after acquiring a majority and controlling stake in Noumed Pharmaceuticals in Australia. The acquisition was completed on November 12, 2025 and Noumed was consolidated from that date, meaning FY26 financials reflect only a part-year inclusion.

The company disclosed it acquired a 74.60% controlling stake in Noumed under a Share Purchase Agreement (SPA) process that included an SPA dated September 24, 2025 and a fresh SPA dated October 24, 2025 due to changes in payment milestones. The structure included an equity infusion of AUD 4.00 million as a primary in Noumed. Separately, Sai Parenterals has also been described as acquiring the stake for ₹125 crore, and as an AUD 22 million (₹125 crore) deal in October 2025.

FY26 performance: Q4 boost and full-year numbers

Sai Parenterals reported that in Q4FY26, the first full quarter of Noumed consolidation, consolidated revenue was ₹198 crore, EBITDA was ₹29 crore, and PAT was ₹13 crore. Another disclosure for the same quarter provided more precise figures: consolidated Q4 FY26 revenue at ₹197.93 crore, EBITDA at ₹28.97 crore, and described year-on-year growth rates of 166.65% for revenue and 366.97% for EBITDA.

For FY26, Sai Parenterals reported consolidated revenue from operations of ₹381 crore, EBITDA of ₹47 crore, and PAT of ₹14 crore. A more detailed disclosure put FY26 consolidated revenue at ₹380.99 crore, EBITDA at ₹47.21 crore, and PAT at ₹14.37 crore, along with growth of 140.37% for revenue, 33.29% for EBITDA, and 45.52% for PAT.

IPO and funding plans

The company said it completed its IPO in March 2026 and raised ₹285 crore. IPO details also cite a total issue size of ₹408.79 crore, comprising a fresh issue of ₹285 crore and an offer-for-sale (OFS) of ₹123.79 crore. The IPO window was listed as opening March 24, 2026 and closing March 27, 2026, with listing expected around April 2, 2026, and a price band of ₹372 to ₹392 per share.

Sai Parenterals has linked the IPO proceeds to capacity expansion, manufacturing upgrades, and the establishment of a dedicated R&D centre in India. The company also cited a broader expansion and upgradation plan across India and Australia, supported by IPO proceeds and additional funding at the subsidiary level.

Capacity expansion and capex: India and Australia

On an earnings call, the CFO described an overall growth capex program of ₹440 crore. He said ₹111 crore is being deployed for capacity expansion and EU-GMP upgrades in India, and ₹18 crore for the R&D center, funded through IPO proceeds.

Separately, the company described Unit III in India as a TGA Australia-approved manufacturing facility, with a plan to expand capacity from 240 million units to 451 million units. The expected completion timeline cited for this expansion is October 2026. In Australia, Noumed has also been described as constructing a new manufacturing plant with an investment of AUD 53 million, with commercial operations expected by calendar Q4 2026.

Regulatory access and product dossier scale

Sai Parenterals highlighted that Noumed provides access to 451 product dossiers and strengthens its presence in the Australian pharmaceutical market. Another set of IPO-related highlights referred to 451+ TGA-approved product registrations and an established presence across Australia and New Zealand with long-term supply agreements.

These disclosures position Noumed as a platform with existing regulatory assets and customer access, while Sai Parenterals brings manufacturing scale in India. The company has also been described as gaining access to hundreds of IP dossiers for filing products in global markets excluding Australia and New Zealand.

Key numbers at a glance

Financial snapshot: Q4FY26 and FY26 consolidated

Market impact: what the disclosures indicate

The most direct market-relevant implication from the disclosures is the addition of a long-duration supply agreement in Australia, with a stated average annual business run-rate of AUD 27 million. The contract start date of July 1, 2026 provides a clear timeline for when this revenue stream begins to flow under the new arrangement.

On the reported financials side, FY26 consolidated performance includes Noumed only from November 12, 2025, and Q4FY26 is stated to be the first full quarter of consolidation. That makes the Q4FY26 numbers a more relevant reference point for assessing the consolidated operating base, while FY26 provides the audited year-end picture including the part-year effect.

Analysis: why the Australia platform is central

Sai Parenterals has explicitly framed the Noumed acquisition as central to its next phase, and the new OTC supply agreement fits that narrative by extending customer-linked revenue visibility in Australia. The company’s disclosures also tie together regulated-market access, product dossiers, and manufacturing investments across India and Australia.

At the execution level, the combination of capacity expansion at a TGA Australia-approved Unit III in India (planned to rise from 240 million to 451 million units by October 2026) and Noumed’s planned Australian manufacturing plant (AUD 53 million, expected by calendar Q4 2026) indicates simultaneous scaling on both sides of the supply chain. Funding references, including the ₹440 crore capex program and the IPO-led allocations for expansion, EU-GMP upgrades, and R&D, provide additional context for how the company intends to support growth.

Conclusion

Sai Parenterals’ Australian subsidiary Noumed has signed an OTC supply agreement valued at AUD 202 million (around ₹1,300 crore), scheduled to start on July 1, 2026 and run for 7.5 years with a potential three-year extension. The deal sits alongside the company’s recent consolidation of Noumed following the completion of a 74.60% acquisition in November 2025. Investors will likely track the July 2026 implementation and the company’s stated timelines for India capacity expansion by October 2026 and Noumed’s planned Australian facility expected to begin commercial operations by calendar Q4 2026.